Description

INVOKANA 100 MG

Indications

INVOKANA (canagliflozin) 100 mg is primarily indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control. INVOKANA can be prescribed alone or in combination with other antidiabetic medications, including metformin, sulfonylureas, or insulin, to enhance the overall effectiveness of diabetes management. Additionally, INVOKANA has shown benefits in reducing the risk of cardiovascular events in patients with established cardiovascular disease.

Mechanism of Action

INVOKANA belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its primary mechanism of action involves the inhibition of SGLT2, a protein in the kidneys responsible for the reabsorption of glucose back into the bloodstream. By blocking this transporter, INVOKANA promotes the excretion of glucose in the urine, thereby lowering blood glucose levels. This mechanism not only helps in glycemic control but also leads to a reduction in body weight and blood pressure, contributing to the overall improvement of cardiovascular health.

Pharmacological Properties

INVOKANA is characterized by its pharmacokinetic properties, which include rapid absorption following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug exhibits a half-life of approximately 10 to 13 hours, allowing for once-daily dosing. INVOKANA is primarily metabolized by the liver through glucuronidation and is excreted in urine and feces. The pharmacodynamics of INVOKANA demonstrate its ability to reduce hemoglobin A1c (HbA1c) levels, improve fasting plasma glucose, and provide additional benefits such as weight loss and blood pressure reduction.

Contraindications

INVOKANA is contraindicated in patients with a known hypersensitivity to canagliflozin or any of its components. It should not be used in individuals with severe renal impairment (eGFR < 30 mL/min), end-stage renal disease, or those on dialysis. Additionally, the use of INVOKANA is not recommended in patients with a history of serious hypersensitivity reactions, such as anaphylaxis or angioedema, related to SGLT2 inhibitors.

Side Effects

Common side effects associated with INVOKANA include urinary tract infections (UTIs), genital mycotic infections, and increased urination. Other potential adverse effects may include dehydration, hypotension, and renal impairment. Serious side effects, although less common, may include ketoacidosis, acute kidney injury, and bone fractures. Patients should be monitored for these effects, especially during the initiation of therapy and when doses are adjusted.

Dosage and Administration

The recommended starting dose of INVOKANA is 100 mg taken orally once daily, preferably before the first meal of the day. In patients who tolerate the initial dose and require additional glycemic control, the dosage may be increased to 300 mg once daily. It is essential to assess renal function prior to initiating treatment and periodically thereafter, as dose adjustments may be necessary based on renal status. INVOKANA can be taken with or without food, but consistent timing with regard to meals is encouraged for optimal glycemic control.

Interactions

INVOKANA may interact with other medications, potentially affecting its efficacy and safety profile. Co-administration with diuretics may increase the risk of dehydration and hypotension. Additionally, drugs that affect renal function, such as non-steroidal anti-inflammatory drugs (NSAIDs) and certain antihypertensives, may alter the pharmacokinetics of INVOKANA. It is crucial to inform healthcare providers of all medications being taken to assess for potential interactions and adjust treatment plans accordingly.

Precautions

Patients using INVOKANA should be cautioned about the risk of dehydration and hypotension, particularly in those with existing volume depletion. Regular monitoring of renal function is recommended, especially in elderly patients and those with pre-existing renal conditions. Due to the risk of ketoacidosis, patients should be educated about the symptoms and advised to seek medical attention if they experience nausea, vomiting, abdominal pain, or unusual fatigue. It is also important to monitor for signs of urinary tract infections and genital infections, as these are more prevalent in patients taking SGLT2 inhibitors.

Clinical Studies

Clinical studies have demonstrated the efficacy of INVOKANA in improving glycemic control in patients with type 2 diabetes. In a pivotal trial, INVOKANA significantly reduced HbA1c levels compared to placebo, with improvements observed as early as 2 weeks after initiation of therapy. Furthermore, studies have indicated that INVOKANA is associated with weight loss and a reduction in systolic blood pressure. Notably, cardiovascular outcomes have been positively influenced, with a reduction in the risk of major adverse cardiovascular events in patients with established cardiovascular disease. These findings support the role of INVOKANA not only in glycemic management but also in the broader context of cardiovascular health.

Conclusion

INVOKANA 100 mg is a valuable therapeutic option for adults with type 2 diabetes, offering effective glycemic control and additional benefits such as weight loss and cardiovascular risk reduction. Understanding its mechanism of action, potential side effects, and interactions is crucial for optimizing patient outcomes. As with any medication, careful monitoring and patient education are essential to ensure safe and effective use.